Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MLNR | O43193 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2796818 | 0.85 | KDM4E (0.48) | EPHX2KMT2AMEN1HTTNPSR1 | |
| SCHEMBL6441529 | 0.84 | EPHX2 (0.54) | EPHX2KMT2AMEN1HTTNPSR1 | |
| SCHEMBL2795216 | 0.82 | KDM4E (0.44) | EPHX2KMT2AMEN1HTTNPSR1 | |
| SCHEMBL13282788 | 0.81 | KMT2A (0.45) | EPHX2KMT2AMEN1HTTMLNR | |
| SCHEMBL6443342 | 0.77 | POLB (0.60) | EPHX2KMT2AMEN1HTTMLNR | |
| SCHEMBL6442744 | 0.77 | EPHX2 (0.52) | EPHX2KMT2AMEN1HTTNPSR1 | |
| SCHEMBL3467491 | 0.76 | HRH1 (0.40) | EPHX2SMN1; SMN2 | |
| SCHEMBL2798799 | 0.75 | CCR1 (0.58) | EPHX2KMT2AMEN1HTTNPSR1 | |
| SCHEMBL6442642 | 0.74 | CCR1 (0.55) | EPHX2KMT2AMEN1HTTNPSR1 | |
| SCHEMBL6439747 | 0.74 | KDM4E (0.65) | EPHX2KMT2AMEN1HTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010077915-A1 | NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077915-A1 | NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-07-08 | — | — | WO | disclosed |
| US-20100168080-A1 | NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-07-01 | — | — | US | disclosed |
| US-20100168080-A1 | NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-07-01 | — | — | US | disclosed |
| US-20100168080-A1 | NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168080-A1 | NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | CCR1, CCR5, CCR3 | EPHX2 1225/4885KMT2A 4409/4885MEN1 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.